Medivir appoints Linda Basse as chief medical officer

Sweden-based Medivir (OMX: MVIR) today revealed it has appointed Linda Basse as Chief Medical Officer effective October 1, 2018.

Dr Basse will report to chief executive Christine Lind and join the Medivir executive team. She replaces Dr John Öhd, who left to join fellow Swedish firm Modus Therapeutics as CMO in March this year.

Dr Basse has more than 18 years of drug development and medical marketing experience, including approvals and marketing of new cancer therapies. Her previous roles include medical director at Zealand Pharma with responsibility for an orphan disease drug candidate and medical director at Genmab with responsibilities leading to the approval of daratumumab and indication expansion of ofatumumab in hematology-oncology indications.